1. Home
  2. PRTA vs FPH Comparison

PRTA vs FPH Comparison

Compare PRTA & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.03

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Logo Five Point Holdings LLC

FPH

Five Point Holdings LLC

N/A

Current Price

$5.12

Market Cap

383.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
FPH
Founded
2012
2009
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
449.7M
383.2M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
PRTA
FPH
Price
$9.03
$5.12
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
471.8K
185.8K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$814,000.00
$110,020,000.00
Revenue This Year
$1,111.38
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$35.73
$11.40
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$4.60
52 Week High
$11.80
$6.64

Technical Indicators

Market Signals
Indicator
PRTA
FPH
Relative Strength Index (RSI) 51.70 48.30
Support Level $8.91 $4.91
Resistance Level $9.36 $5.16
Average True Range (ATR) 0.41 0.14
MACD 0.05 -0.01
Stochastic Oscillator 70.19 24.19

Price Performance

Historical Comparison
PRTA
FPH

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: